Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Refractive Surgery/Vision Correction > Contact Lenses > A Potential Alternative to Available RGP Lens Solutions
  • Contact Lenses

A Potential Alternative to Available RGP Lens Solutions

Ophthalmology 360
Article Image

A povidone-iodine based solution may be a viable alternative to other solutions for rigid gas permeable contact lenses, according to a recent analysis. 

Investigators evaluated bactericidal and fungicidal occurrences, as well as amoebicidal properties for the new solution and 3 currently-available solutions. In particular, they assessed storage stability over 3 months. Among the results:

  • FDA guidelines were achieved by all solutions.
  • Activity against bacteria and fungus was not impacted by 3-month storage for any of the solutions. 
  • Activity against Acanthamoeba castellani trophozoites was reduced by 1-log for the povidone-iodine solution; it was reduced nearly as much for the remaining solutions. 
  • Activity against cysts was somewhat impacted, ranging between 78% and 86% reduced viability for the solutions analyzed.

Cho P, Reyes S, Boost M. Microbiocidal characterization of a novel povidone-iodine based rigid contact lens disinfecting solution. Cont Lens Anterior Eye. 2018 Dec;41(6):542-546 . doi: 10.1016/j.clae.2018.08.001.   

Share

Related Content

  • Contact Lenses

Blue-violet filtering contact lenses improve contrast sensitivity in low light and glare

  • Spotlight Series

Spotlight on ACUVUE®

contact lens
  • Optometry

Customize contact lens selection to avoid dropout in presbyopic patients

contact lens
  • Contact Lenses

Understanding contact lens wearers’ attitudes could help decrease improper use

  • Contact Lenses

Quiz: Contact Lens-Related Complications

  • Exclusives

Novel Visual Alignment Technology for Practice Growth

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon